The TP53 gene encodes the p53 protein, often referred to as the ‘guardian of the genome’ due to its critical role in maintaining genomic stability and preventing tumorigenesis. Under normal conditions, p53 expression is tightly regulated by MDM2 and MDMX, which promote its degradation through ubiquitination. In response to endogenous or exogenous stress, this ubiquitination process is inhibited, leading to the stabilization of p53. Once stabilized, p53 forms a tetrameric complex in the nucleus and binds to DNA. It then activates the transcription of genes involved in cell cycle arrest, DNA repair, apoptosis, and senescence, aiming either to repair DNA damage or eliminate cells when the damage is irreparable. Nearly half of all cancer cases involve mutations in the TP53 gene. These mutations may include missense, nonsense, inframe, and splice-site mutations. Mutations in TP53 result in the production of mutant p53 (mutp53) proteins. These mutations can lead to a loss of tumor suppressor function or confer gain-of-function properties that promote tumor progression. Given its central role in cancer development, TP53 is considered a promising therapeutic target. Potential strategies include reactivating suppressed p53, restoring the function of mutp53, or inducing its degradation.

Adi, A. A. A. M., Putra, I. G. A. A., & Sewoyo, P. S. (2023). Potensi Virus Newcastle Disease untuk viroterapi kanker. Deepublish.

Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., Parenti, A. R., Rosato, A., Bicciato, S., Balmain, A., & Piccolo, S. (2009). A mutant-p53/Smad complex opposes p63 to empower TGF-β-induced metastasis. Cell, 137(1), 87–98.

Aguilar, A., & Wang, S. (2023). Therapeutic strategies to activate p53. Pharmaceuticals, 16(1), 24.

Amelio, I., Mancini, M., Petrova, V., Cairns, R. A., Vikhreva, P., Nicolai, S., Marini, A., Antonov, A. A., Le Quesne, J., Baena Acevedo, J. D., Dudek, K., Sozzi, G., Pastorino, U., Knight, R. A., Mak, T. W., & Melino, G. (2018). p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 115(46), E10869–E10878.

Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018). How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death & Differentiation, 25(1), 104–113.

Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014). Unravelling mechanisms of p53-mediated tumour suppression. Nature Reviews Cancer, 14(5), 359–370.

Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., & Fearon, E. R. (2007). p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Current Biology, 17(15), 1298–1307.

Borrero, L. J. H., & El-Deiry, W. S. (2021). Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1876(1), 188556.

Bykov, V. J., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018). Targeting mutant p53 for efficient cancer therapy. Nature Reviews Cancer, 18(2), 89–102.

Canadillas, J. M., Tidow, H., Freund, S. M., Rutherford, T. J., Ang, H. C., & Fersht, A. R. (2006). Solution structure of p53 core domain: Structural basis for its instability. Proceedings of the National Academy of Sciences, 103(7), 2109–2114.

Capaci, V., Mantovani, F., & Del Sal, G. (2021). Amplifying tumor-stroma communication: An emerging oncogenic function of mutant p53. Frontiers in Oncology, 10, 614230.

Chasov, V., Mirgayazova, R., Zmievskaya, E., Khadiullina, R., Valiullina, A., Stephenson Clarke, J., & Bulatov, E. (2020). Key players in the mutant p53 team: Small molecules, gene editing, immunotherapy. Frontiers in Oncology, 10, 1460.

Chen, L., Liu, S., & Tao, Y. (2020). Regulating tumor suppressor genes: Post-translational modifications. Signal Transduction and Targeted Therapy, 5(1), 90.

Chen, Y., Zhang, X., Dantas Machado, A. C., Ding, Y., Chen, Z., Qin, P. Z., & Chen, L. (2013). Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion. Nucleic Acids Research, 41(17), 8368–8376.

Chiang, Y. T., Chien, Y. C., Lin, Y. H., Wu, H. H., Lee, D. F., & Yu, Y. L. (2021). The function of the mutant p53-R175H in cancer. Cancers, 13(16), 4088.

Costa, D. C., de Oliveira, G. A., Cino, E. A., Soares, I. N., Rangel, L. P., & Silva, J. L. (2016). Aggregation

and prion-like properties of misfolded tumor suppressors: Is cancer a prion disease? Cold Spring Harbor Perspectives in Biology, 8(10), a023614.

Dong, P., Karaayvaz, M., Jia, N., Kaneuchi, M., Hamada, J., Watari, H., Sudo, S., Ju, J., & Sakuragi, N. (2013). Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b–ZEB1 axis. Oncogene, 32(27), 3286–3295.

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., & Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75(4), 817–825.

Engeland, K. (2022). Cell cycle regulation: p53-p21-RB signaling. Cell Death & Differentiation, 29(5), 946–960.

Fischer, M., Quaas, M., Steiner, L., & Engeland, K. (2016). The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Research, 44(1), 164–174.

Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002). A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proceedings of the National Academy of Sciences, 99(2), 937–942.

Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001). A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Molecular and Cellular Biology, 21(5), 1874–1887.

Ghate, N. B., Kim, J., Shin, Y., Situ, A., Ulmer, T. S., & An, W. (2019). p32 is a negative regulator of p53 tetramerization and transactivation. Molecular Oncology, 13(9), 1976–1992.

Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., & Mitchell, J. B. (2012). Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proceedings of the National Academy of Sciences of the United States of America, 109(29), 11788–11793.

Gu, B., & Zhu, W. (2012). Surf the post-translational modification network of p53 regulation. International Journal of Biological Sciences, 8(5), 672–684.

Guo, Z., Tsai, M.-H., Shiao, Y.-H., Chen, L.-H., Wei, M.-L., Lv, X., Gius, D., Little, J. B., Mitchell, J. B., & Chuang, E. Y. (2008). DNA (cytosine-5)-methyltransferase 1 as a mediator of mutant p53-determined p16(INK4A) down-regulation. Journal of Biomedical Science, 15(2), 163–168.

Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019). The multiple mechanisms that regulate p53 activity and cell fate. Nature Reviews Molecular Cell Biology, 20(4), 199–210.

Hermeking, H., Lengauer, C., Polyak, K., He, T. C., Zhang, L., Thiagalingam, S., & Vogelstein, B. (1997). 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Molecular Cell, 1(1), 3–11.

Igbinehi, E., Jeremiah, M., & David, I. (2024). The tumor suppressor gene p53: Insights into its function in cancer and potential therapeutic approaches. Journal of Cancer Biology and Research, 10(1), 1–4.

Jasik, A., Kycko, A., Olech, M., Wyrostek, K., Śmiech, A., Łopuszyński, W., & Dolka, I. (2021). Mutations of p53 gene in canine sweat gland carcinomas probably associated with UV radiation. Journal of Veterinary Research, 65(4), 519–528.

Ji, L., Xu, J., Liu, J., Amjad, A., Zhang, K., Liu, Q., Zhou, L., Xiao, J., & Li, X. (2015). Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway. Journal of Biological Chemistry, 290(18), 11729–11740.

Joerger, A. C., & Fersht, A. R. (2016). The p53 pathway: Origins, inactivation in cancer, and emerging therapeutic approaches. Annual Review of Biochemistry, 85, 375–404.

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Leiserson, M. D. M., Phillips, J., Lawrence, M. S., & Raphael, B. J. (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502(7471), 333–339.

Khromova, N. V., Kopnin, P. B., Stepanova, E. V., Agapova, L. S., & Kopnin, B. P. (2009). p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Letters, 276(2), 143–151.

Koshino, A., Goto-Koshino, Y., Setoguchi, A., Ohno, K., & Tsujimoto, H. (2016). Mutation of p53 gene and its correlation with the clinical outcome in dogs with lymphoma. Journal of Veterinary Internal Medicine, 30(1), 223–229.

Lai, M. Y., Chang, H. C., Li, H. P., Ku, C. K., Chen, P. J., Sheu, J. C., Lee, C. S., Wu, Y. J., & Chen, D. S. (1993). Splicing mutations of the p53 gene in human hepatocellular carcinoma. Cancer Research, 53(8), 1653–1656.

Lakin, N., & Jackson, S. (1999). Regulation of p53 in response to DNA damage. Oncogene, 18(53), 7644–7655.

Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., & Vogelstein, B. (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Research, 53(10), 2231–2234.

Leu, J. I. J., Dumont, P., Hafey, M., Murphy, M. E., & George, D. L. (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex. Nature Cell Biology, 6(5), 443–450.

Levine, A. J. (2020). p53: 800 million years of evolution and 40 years of discovery. Nature Reviews Cancer, 20(8), 471–480.

Li, D., Marchenko, N. D., & Moll, U. M. (2011). SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death & Differentiation, 18(12), 1904–1913.

Lin, K., Rockliffe, N., Johnson, G. G., Sherrington, P. D., & Pettitt, A. R. (2008). Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene, 27(17), 2445–2455.

Liu, D., Sun, Q., Liang, S., Xu, L., Luo, X., Zhao, X., Wang, X., & Yang, L. (2013). MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells. Molecular Medicine Reports, 7(2), 642–648.

Marine, J. C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006). Keeping p53 in check: Essential and synergistic functions of Mdm2 and Mdm4. Cell Death & Differentiation, 13(6), 927–934.

Moran, D. M., & Maki, C. G. (2010). Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Molecular Cancer Therapeutics, 9(4), 895–905.

Muller, P. A. J., & Vousden, K. H. (2014). Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell, 25(3), 304–317.

Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukacs, C., Liao, Z., & Vousden, K. H. (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell, 139(7), 1327–1341.

Nakano, K., & Vousden, K. H. (2001). PUMA, a novel proapoptotic gene, is induced by p53. Molecular Cell, 7(3), 683–694.

Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014). Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. eLife, 3, e02872.

Nikolova, P. V., Wong, K. B., DeDecker, B., Henckel, J., & Fersht, A. R. (2000). Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. The EMBO Journal, 19(3), 370–378.

Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., & Tanaka, N. (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 288(5468), 1053–1058.

Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L. & Vogelstein, B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80–83.

Oliner, J.D., Saiki, A.Y. & Caenepeel, S. (2016). The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harbor Perspectives in Medicine, 6, a026336.

Phang, B.H., Othman, R., Bougeard, G., Chia, R.H., Frebourg, T., Tang, C.L. & Sabapathy, K. (2015). Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 112(46), E6349–E6358.

Quinn, E.A., Maciaszek, J.L., Pinto, E.M., Phillips, A.H., Berdy, D., Khandwala, M. & Kesserwan, C. (2019). From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. Molecular Case Studies, 5(4), a003921.

Ryan, K.M. & Vousden, K.H. (1998). Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Molecular and Cellular Biology, 18, 3692–3698.

Sallman, D.A., DeZern, A.E., Garcia-Manero, G., Steensma, D.P., Roboz, G.J., Sekeres, M.A., Cluzeau, T., Sweet, K.L., McLemore, A., McGraw, K.L. & List, A.F. (2021). Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 39, 1584–1594.

Schulz-Heddergott, R. & Moll, U.M. (2018). Gain-of-function (GOF) mutant p53 as actionable therapeutic target. Cancers. 10, 188.

Sewoyo, P.S., Astawa, I.N.M., Adi, A.A.A.M., Suardana, I.B.K., Winaya, I.B.O. & Berata, I.K. (2025). Newcastle disease virus Tabanan-1/ARP/2017 suppresses Ki67 and VEGF expression in rat mammary carcinoma models. Veterinarski Arhiv (Ahead of Print).

Shangary, S. & Wang, S. (2009). Small-molecule inhibitors of the MDM2–p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annual Review of Pharmacology and Toxicology. 49, 223–241.

Shirole, N.H., Pal, D., Kastenhuber, E.R., Senturk, S., Boroda, J., Pisterzi, P. & Sordella, R. (2016). TP53 exon-6 truncating mutations produce separation-of-function isoforms with pro-tumorigenic functions. eLife. 5, e17929.

Soragni, A., Janzen, D.M., Johnson, L.M., Lindgren, A.G., Nguyen, A.T.Q., Tiourin, E. & Eisenberg, D.S. (2016). A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell, 29(1), 90–103.

Stiewe, T. & Haran, T.E. (2018). How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resistance Updates, 38, 27–43.

Stommel, J.M., Marchenko, N.D., Jimenez, G.S., Moll, U.M., Hope, T.J. and Wahl, G.M. (1999). A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. The EMBO Journal, 18, 1660–1672.

Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M.G., Monti, O., Baccarini, A., Sacchi, A., Blandino, G. & Dell'Orso, S. (2002). Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. Journal of Biological Chemistry. 277, 18817–18826.

Subramanian, M., Francis, P., Bilke, S., Li, X.L., Hara, T., Lu, X. & Lal, A. (2015). A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene, 34(9), 1094–1104.

Sullivan, K.D., Galbraith, M.D., Andrysik, Z. & Espinosa, J.M. (2018). Mechanisms of transcriptional regulation by p53. Cell Death and Differentiation, 25, 133–143.

Tan, B.S., Tiong, K.H., Choo, H.L., Chung, F.F., Hii, L.W., Tan, S.H., Yap, I.K., Pani, S., Khor, N.T., Wong, S.F., Rosli, R., Cheong, S.K. & Leong, C.O. (2015). Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death and Disease, 6(7), e1826.

Tanaka, T., Watanabe, M. & Yamashita, K. (2018). Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. Oncotarget, 9(22), 16234.

Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A. & Hermeking, H. (2007). Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 6(13), 1586–1593.

Taritsa, I.C. & Fossel, E.T. (2025). Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53. Frontiers in Pharmacology, 16, 1529483.

Taylor, W.R. & Stark, G.R. (2001). Regulation of the G2/M transition by p53. Oncogene, 20, 1803–1815.

Valentino, E., Bellazzo, A., Di Minin, G., Sicari, D., Apollonio, M., Scognamiglio, G. & Collavin, L. (2017). Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP. Proceedings of the National Academy of Sciences of the United States of America. 114(29), 7623–7628.

Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C. & Liu, E.A. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303(5659), 844–848.

Vousden, K.H. & Prives, C. (2009). Blinded by the light: the growing complexity of p53. Cell, 137(3), 413–431.

Wang, J., Zhao, Q., Qi, Q., Gu, H., Rong, J., Mu, R., Zou, M., Tao, L., You, Q. & Guo, Q. (2011). Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. Journal of Cellular Biochemistry, 112, 509–519.

Wei, H., Qu, L., Dai, S., Li, Y., Wang, H., Feng, Y. & Chen, Y. (2021). Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis. Nature Communications, 12(1), 2280.

West, A.C. & Johnstone, R.W. (2014). New and emerging HDAC inhibitors for cancer treatment. Journal of Clinical Investigation, 124, 30–39.

White, E. (2016). Autophagy and p53. Cold Spring Harbor Perspectives in Medicine, 6, a026120.

Wu, G.S., Kim, K. & El-Deiry, W.S. (2000). KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Advances in Experimental Medicine and Biology, 465, 143–151.

Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X. & Chen, X. (2013). Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene, 32, 599–609.

Zhang, W., Guo, X.Y., Hu, G.Y., Liu, W.B., Shay, J.W. & Deisseroth, A.B. (1994). A temperature-sensitive mutant of human p53. The EMBO Journal, 13, 2535–2544.

Zhu, G., Pan, C., Bei, J.X., Li, B., Liang, C., Xu, Y. & Fu, X. (2020). Mutant p53 in cancer progression and targeted therapies. Frontiers in Oncology, 10, 595187.